Register now and get 10% first deposit bonus. Close advertisement

Moderna Inc. (MRNA) live price

Discover historical price data for Moderna Inc stocks and take your profit on price changes.


1 day
1 week
1 month
136.37 USD 4.78715%
Buy Sell

Moderna stock has caused a stir in the stock market in 2020-2021. The company is one of the leading manufacturers of vaccines against COVID-19. Sales of coronavirus drugs have generated billions of dollars for the corporation. To see how investors feel about this biotech giant, check out analysts' stock price forecasts for Moderna in the coming years.

Moderna logo

Basic company information

Moderna is a biotechnology company headquartered in Cambridge, Massachusetts. It was founded in 2010. Stephan Buncel and Derrick Jones. Moderna's mRNA platform is based on technology licensed from Merck Co. Moderna has received funding from several investors, including Bill Gates, Google Ventures, and NIH.

Moderna was listed on the Nasdaq Stock Exchange on December 6, 2018, and raised $604 million in an initial public offering. As of October 2019, the company had a market capitalization of $8.7 billion. Moderna's stock price has been volatile since its IPO, due in part to the risk inherent in investing in a biotech company that does not have approved products. However, the company's stock has been trending upward in recent months as the development of potential treatments and vaccines nears completion. With several promising candidates in clinical trials and a solid financial position, Moderna is well-positioned for future success.

The company's activity

In its early days, Moderna focused on the development of messenger RNA (mRNA)-based vaccines and therapeutics. In 2013, the company published work describing the use of mRNA to encode antibodies against the influenza virus. This work laid the foundation for Moderna's subsequent clinical development of mRNA-based vaccines and therapeutics.

Moderna's first product, an influenza vaccine, was approved by the U.S. Food and Drug Administration (FDA) in 2018. Moderna is also developing mRNA-based therapies for cancer and other diseases. The company collaborates with several academic institutions and pharmaceutical companies, including Merck, Pfizer, and Sanofi.

The latest news on the stock price

In October 2022, it was revealed that the company was working with drug maker Merck on a cancer vaccine. Following this news, Moderna's stock price rose 16%. Moderna's anti-cancer vaccine is now in Phase II trials. It is being tested in combination with Merck's cancer drug Keytruda. Work on the cancer vaccine allows the pharmaceutical giant to alleviate investor concerns about the narrow specialization of the corporation, now known mainly for developing drugs for COVID-19.

On Oct. 21, 2022, Moderna shares gained 8.4 percent after it was reported that Pfizer plans to raise the price of its vaccine in 2023. The U.S. government now pays $30.5 per dose of Pfizer's vaccine. The drug company says the cost per shot of the drug could rise to $130 in 2023. For most COVID-19 vaccine manufacturers, this could mean higher drug costs. For Moderna, analysts also raised sales estimates for next year.

✅ Benefits of investing in Moderna

  • The corporation is gearing up for the post-pandemic period and is working to expand beyond producing COVID-19 vaccines. Moderna is working on more than 40 programs, most of which have nothing to do with treating or preventing coronavirus. The company is researching vaccines against influenza, respiratory syncytial virus, and cytomegalovirus.
  • At the beginning of the coronavirus pandemic, the company generated huge revenues from vaccine sales. The vaccination wave subsided in the second half of 2022, but sales of booster doses of the COVID-19 vaccine continue to generate revenue for the pharmaceutical giant.

❌ Disadvantages of Investing in Moderna

  • Many investors believe that Moderna stock was only in demand in the stock market while the company was actively working on the COVID-19 vaccine. In 2022, the pharmaceutical giant's name continues to be associated with the coronavirus, particularly the development of the Spikevax vaccine. This point has alarmed investors focused on long-term investments. They believe the company will be less popular in the future when the number of COVID-19 illnesses is significantly reduced.
  • The corporation faces stiff competition from other biotech companies, which could limit its growth potential.

Financial performance

The biotech giant finished the second quarter of 2022 with revenues of $4.7 billion. This was 6.8% higher than the result for the same reporting period in 2021, which was at $4.4 billion. The corporation's net income reached $2.2 billion. This figure was 27% behind the second quarter of 2021. However, pharma sales increased by 9% compared to this reporting period. That figure reached $4.7 billion in the second quarter of 2022.

Moderna's stock has lost about 50% of its value over the past year. The market capitalization of the biotech giant in 2022 was $50 billion. Despite the fall in quotations, MRNA Stock has sufficient growth potential. For example, following the release of the corporation's financial report for the second quarter of 2022, Moderna stock was up 17% the moment, according to the NASDAQ stock exchange.

Moderna stock price forecast for 2023, 2025, and 2030

Moderna's stock price is already relatively high, which means less upside potential. Our price target for Moderna in the coming years is based on the daily price target for Moderna shares as of October 25, 2022, which values the stock at $133. According to the technical analysis, in 2023, MRNA stock will trade at $160-180. By 2025, this asset has the potential to rise to the $300 mark or higher. If the flu vaccines currently in development are successful, Moderna stock could increase to $500 or more by 2030.

Answers to Frequently Asked Questions

How has the COVID-19 pandemic affected Moderna's stock price?

In March 2020, Moderna stock was trading at $28. After the pandemic began, the corporation was developing a vaccine for COVID-19. In November 2020, Moderna's stock price went into high gear and reached $380 in September 2021. 

How does an individual invest in MRNA stock?

To start investing in Moderna stock, log into your personal DotBig account, fund your trading account, and start your trading terminal.

How has Moderna's stock price changed over the past year?

From October 2021 to October 2022, Moderna's stock price dropped from $343 to $133.

Can MRNA stock be traded automatically?

For investing in the stock market in automatic mode, DotBig offers a free trading signal service, trading robots, and a copy trading platform.

What other biotech companies can I choose to invest in?

You can choose to invest in biotech companies such as Zogenix, Vaxart, Biogen, ALX Oncology Holdings, and Pfizer.

How to start trading Moderna Inc stocks



To authorize on the website and create a personal account, fill out the form, indicating your name, phone number, email address.



After registration, provide an identity document to verify your age and place of residence.


Replenish your account

To start trading real money, the initial deposit can be made in any available way.



You can open/close deals on your own under the guidance of an experienced analyst or copy them from other traders.

AnnLightner $63,842.90
1487 folowers
Cristian86 $59,763.88
1429 folowers
Trust_Trader $47,655.23
1250 folowers
Suitable for beginners

Copy top Moderna Inc traders

No trading experience? Not a problem! With social trading, you can copy the trades of the best DotBig traders. Follow the rating and make a profit.

Start trading

Get daily trading signals for Moderna Inc from our experts

Scroll to top